STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	Regulatory progress for VivaGel BV in the US		23/05/19	57.68KB	Share
SPL	Starpharma to present at US Drug Delivery Conference		07/05/19	1.67MB	Share
SPL	Starpharma presents at Macquarie Australia Conference		01/05/19	108.68KB	Share
SPL	Ceasing to be a substantial holder		01/05/19	201.13KB	Share
SPL	Quarterly Cashflow Report	PRICE SENSITIVE	29/04/19	172.39KB	Share
SPL	First VivaGel BV launch globally in Australia by Aspen	PRICE SENSITIVE	16/04/19	127.48KB	Share
SPL	Starpharma meets with US FDA to discuss VivaGel BV		11/04/19	112.24KB	Share
SPL	Starpharma Investor Presentation to Goldman Sachs Conference		03/04/19	3.61MB	Share
SPL	Appendix 3B		19/03/19	171.26KB	Share
SPL	Shareholder Update March 2019		18/03/19	452.31KB	Share
SPL	Starpharma receives $4.0M R&D tax incentive refund	PRICE SENSITIVE	12/03/19	117.6KB	Share
SPL	Interim Report and Half-Yearly Financial Results	PRICE SENSITIVE	27/02/19	765.59KB	Share
SPL	Appendix 3B		08/02/19	177.71KB	Share
SPL	Quarterly Cashflow Report	PRICE SENSITIVE	30/01/19	309.77KB	Share
SPL	Shareholder Update January 2019		17/01/19	556.79KB	Share
SPL	Becoming a substantial holder		14/01/19	495.15KB	Share
SPL	Response to ASX Aware Letter	PRICE SENSITIVE	07/01/19	445.4KB	Share
SPL	VivaGel condom receives final regulatory approval in Japan	PRICE SENSITIVE	02/01/19	113.95KB	Share
SPL	Change in Director's Interest Notice - P Turvey		28/12/18	72.8KB	Share
SPL	Change in Director's Interest Notice - J Fairley		28/12/18	73.28KB	Share
SPL	Change in Director's Interest Notice - R Thomas		28/12/18	73.67KB	Share
SPL	US FDA requests further data for VivaGel BV approval	PRICE SENSITIVE	27/12/18	128.38KB	Share
SPL	Ceasing to be a substantial holder		27/12/18	484.7KB	Share
SPL	US VivaGel BV licensed for A$142M milestones plus royalties	PRICE SENSITIVE	20/12/18	134.83KB	Share
SPL	US patent granted for SPL7013 eye drops for conjunctivitis		12/12/18	56.3KB	Share
SPL	Change in Director's Interest Notice - J Fairley		11/12/18	130.03KB	Share
SPL	Appendix 3B		11/12/18	177.29KB	Share
SPL	Becoming a substantial holder		11/12/18	494.99KB	Share
SPL	AGM Results		29/11/18	156.07KB	Share
SPL	AGM - Chairman address and CEO presentation	PRICE SENSITIVE	29/11/18	4.08MB	Share
SPL	DEP products outperform in human pancreatic cancer model	PRICE SENSITIVE	16/11/18	377.73KB	Share
SPL	Appendix 3B		05/11/18	173.41KB	Share
SPL	Notice of General Meeting/Proxy Form		26/10/18	812.04KB	Share
SPL	Quarterly Cashflow Report	PRICE SENSITIVE	26/10/18	312.5KB	Share
SPL	Starpharma Investor Presentation for Citi Conference	PRICE SENSITIVE	17/10/18	2.9MB	Share
SPL	Ceasing to be a substantial holder		08/10/18	494.3KB	Share
SPL	Change in Director's Interest Notice - J Fairley		05/10/18	139.98KB	Share
SPL	Appendix 3B		05/10/18	168.86KB	Share
SPL	Notification of AGM date		02/10/18	109.83KB	Share
SPL	Change in substantial holding		14/09/18	513.52KB	Share
SPL	DEP irinotecan outperforms in pancreatic cancer model	PRICE SENSITIVE	05/09/18	154.02KB	Share
SPL	AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy	PRICE SENSITIVE	31/08/18	140.72KB	Share
SPL	Appendix 4G - Corporate Governance Statement		21/08/18	181.05KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	21/08/18	3.6MB	Share
SPL	Quarterly Cashflow Report	PRICE SENSITIVE	17/07/18	227.14KB	Share
SPL	VivaGel BV NDA advances to next stage of FDA review	PRICE SENSITIVE	09/07/18	119.38KB	Share
SPL	Starpharma licenses VivaGel BV to Mundipharma for Europe	PRICE SENSITIVE	27/06/18	141.64KB	Share
SPL	Change in substantial holding		06/06/18	534.98KB	Share
SPL	Change in Director's Interest Notice - R Thomas		17/05/18	120.43KB	Share
SPL	Mundipharma licenses Starpharma's VivaGel BV	PRICE SENSITIVE	03/05/18	153.35KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/04/18	239.17KB	Share
SPL	Starpharma completes US New Drug Application for VivaGel BV	PRICE SENSITIVE	30/04/18	147.44KB	Share
SPL	Starpharma to present at OTCQX Virtual Investor Conference		11/04/18	53.5KB	Share
SPL	Change in Director's Interest Notice - J Fairley		21/03/18	131.78KB	Share
SPL	Change in Director's Interest Notice - R Thomas		20/03/18	116.78KB	Share
SPL	Appendix 3B		20/03/18	183.54KB	Share
SPL	Change in Director's Interest Notice - R Thomas		15/03/18	116.9KB	Share
SPL	Change in Director's Interest Notice - P Turvey		12/03/18	116.36KB	Share
SPL	Change in Director's Interest Notice - J Fairley		12/03/18	74.12KB	Share
SPL	Change in Director's Interest Notice - R Thomas		05/03/18	139.99KB	Share
SPL	Interim Report and Half-Yearly Financial Results	PRICE SENSITIVE	26/02/18	467.21KB	Share
SPL	Starpharma receives $3.7M R&D tax incentive refund	PRICE SENSITIVE	22/02/18	125.51KB	Share
SPL	Shareholder Update February 2018		19/02/18	1.51MB	Share
SPL	Starpharma to commence DEP cabazitaxel phase 1/2 trial	PRICE SENSITIVE	31/01/18	146.38KB	Share
SPL	Appendix 3B		29/01/18	186.06KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	25/01/18	690.96KB	Share
SPL	VivaGel BV treatment clinical submission under rolling NDA	PRICE SENSITIVE	21/12/17	166.62KB	Share
SPL	Change in Director's Interest Notice - J Fairley		11/12/17	257.79KB	Share
SPL	Appendix 3B		11/12/17	189.62KB	Share
SPL	Change in Director's Interest Notice - R Thomas		05/12/17	257.4KB	Share
SPL	Amended Constitution		29/11/17	898.26KB	Share
SPL	AGM Results		29/11/17	131.25KB	Share
SPL	AGM - Chairman address and CEO presentation		29/11/17	5.95MB	Share
SPL	NDA submission for VivaGel BV in the US	PRICE SENSITIVE	21/11/17	159.47KB	Share
SPL	Change in Director's Interest Notice - J Fairley		08/11/17	70.24KB	Share
SPL	Change in Director's Interest Notice - R Thomas		31/10/17	118.79KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		27/10/17	642.28KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	26/10/17	231.4KB	Share
SPL	VivaGel BV granted marketing approval in Australia	PRICE SENSITIVE	25/10/17	83.81KB	Share
SPL	Shareholder Update October 2017		18/10/17	1.23MB	Share
SPL	Appendix 3B		12/10/17	115.54KB	Share
SPL	Starpharma and Peter Mac Cancer Centre awarded DEP Grant	PRICE SENSITIVE	09/10/17	58.58KB	Share
SPL	Change in Director's Interest Notice - J Fairley		05/10/17	128.52KB	Share
SPL	Appendix 3B		05/10/17	185.46KB	Share
SPL	Notification of AGM date		02/10/17	115.87KB	Share
SPL	AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor	PRICE SENSITIVE	28/09/17	138.54KB	Share
SPL	DEP docetaxel positive phase 1 results, phase 2 commences	PRICE SENSITIVE	22/09/17	363.52KB	Share
SPL	Appendix 4G - Corporate Governance Statement		28/08/17	186.46KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	28/08/17	1.77MB	Share
SPL	Starpharma to present at Finance News Network Investor Event		24/08/17	122.2KB	Share
SPL	Appendix 3B		21/08/17	184.22KB	Share
SPL	Starpharma and Monash awarded STEM Business Fellowships	PRICE SENSITIVE	09/08/17	138.26KB	Share
SPL	Successful VivaGel Phase 3 results and NDA planned for rBV	PRICE SENSITIVE	07/08/17	424.4KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	19/07/17	169.14KB	Share
SPL	Shareholder Update July 2017		04/07/17	710.25KB	Share
SPL	VivaGel BV phase 3 results timing and commercialisation	PRICE SENSITIVE	04/07/17	173.13KB	Share
SPL	Appendix 3B		14/06/17	184.95KB	Share
SPL	Sale of Agrochemicals Business Investor Presentation		14/06/17	986.91KB	Share
SPL	Starpharma sells Agrochemicals business to Agrium for $35M	PRICE SENSITIVE	14/06/17	179.92KB	Share
SPL	DEP irinotecan outperforms irinotecan in cancer models	PRICE SENSITIVE	06/06/17	349.39KB	Share

SPL Regulatory progress for VivaGel BV in the US
23/05/19		57.68KB	Share
SPL Starpharma to present at US Drug Delivery Conference
07/05/19		1.67MB	Share
SPL Starpharma presents at Macquarie Australia Conference
01/05/19		108.68KB	Share
SPL Ceasing to be a substantial holder
01/05/19		201.13KB	Share
SPL Quarterly Cashflow Report
29/04/19	PRICE SENSITIVE	172.39KB	Share
SPL First VivaGel BV launch globally in Australia by Aspen
16/04/19	PRICE SENSITIVE	127.48KB	Share
SPL Starpharma meets with US FDA to discuss VivaGel BV
11/04/19		112.24KB	Share
SPL Starpharma Investor Presentation to Goldman Sachs Conference
03/04/19		3.61MB	Share
SPL Appendix 3B
19/03/19		171.26KB	Share
SPL Shareholder Update March 2019
18/03/19		452.31KB	Share
SPL Starpharma receives $4.0M R&D tax incentive refund
12/03/19	PRICE SENSITIVE	117.6KB	Share
SPL Interim Report and Half-Yearly Financial Results
27/02/19	PRICE SENSITIVE	765.59KB	Share
SPL Appendix 3B
08/02/19		177.71KB	Share
SPL Quarterly Cashflow Report
30/01/19	PRICE SENSITIVE	309.77KB	Share
SPL Shareholder Update January 2019
17/01/19		556.79KB	Share
SPL Becoming a substantial holder
14/01/19		495.15KB	Share
SPL Response to ASX Aware Letter
07/01/19	PRICE SENSITIVE	445.4KB	Share
SPL VivaGel condom receives final regulatory approval in Japan
02/01/19	PRICE SENSITIVE	113.95KB	Share
SPL Change in Director's Interest Notice - P Turvey
28/12/18		72.8KB	Share
SPL Change in Director's Interest Notice - J Fairley
28/12/18		73.28KB	Share
SPL Change in Director's Interest Notice - R Thomas
28/12/18		73.67KB	Share
SPL US FDA requests further data for VivaGel BV approval
27/12/18	PRICE SENSITIVE	128.38KB	Share
SPL Ceasing to be a substantial holder
27/12/18		484.7KB	Share
SPL US VivaGel BV licensed for A$142M milestones plus royalties
20/12/18	PRICE SENSITIVE	134.83KB	Share
SPL US patent granted for SPL7013 eye drops for conjunctivitis
12/12/18		56.3KB	Share
SPL Change in Director's Interest Notice - J Fairley
11/12/18		130.03KB	Share
SPL Appendix 3B
11/12/18		177.29KB	Share
SPL Becoming a substantial holder
11/12/18		494.99KB	Share
SPL AGM Results
29/11/18		156.07KB	Share
SPL AGM - Chairman address and CEO presentation
29/11/18	PRICE SENSITIVE	4.08MB	Share
SPL DEP products outperform in human pancreatic cancer model
16/11/18	PRICE SENSITIVE	377.73KB	Share
SPL Appendix 3B
05/11/18		173.41KB	Share
SPL Notice of General Meeting/Proxy Form
26/10/18		812.04KB	Share
SPL Quarterly Cashflow Report
26/10/18	PRICE SENSITIVE	312.5KB	Share
SPL Starpharma Investor Presentation for Citi Conference
17/10/18	PRICE SENSITIVE	2.9MB	Share
SPL Ceasing to be a substantial holder
08/10/18		494.3KB	Share
SPL Change in Director's Interest Notice - J Fairley
05/10/18		139.98KB	Share
SPL Appendix 3B
05/10/18		168.86KB	Share
SPL Notification of AGM date
02/10/18		109.83KB	Share
SPL Change in substantial holding
14/09/18		513.52KB	Share
SPL DEP irinotecan outperforms in pancreatic cancer model
05/09/18	PRICE SENSITIVE	154.02KB	Share
SPL AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
31/08/18	PRICE SENSITIVE	140.72KB	Share
SPL Appendix 4G - Corporate Governance Statement
21/08/18		181.05KB	Share
SPL Annual report and full year financial results
21/08/18	PRICE SENSITIVE	3.6MB	Share
SPL Quarterly Cashflow Report
17/07/18	PRICE SENSITIVE	227.14KB	Share
SPL VivaGel BV NDA advances to next stage of FDA review
09/07/18	PRICE SENSITIVE	119.38KB	Share
SPL Starpharma licenses VivaGel BV to Mundipharma for Europe
27/06/18	PRICE SENSITIVE	141.64KB	Share
SPL Change in substantial holding
06/06/18		534.98KB	Share
SPL Change in Director's Interest Notice - R Thomas
17/05/18		120.43KB	Share
SPL Mundipharma licenses Starpharma's VivaGel BV
03/05/18	PRICE SENSITIVE	153.35KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/04/18	PRICE SENSITIVE	239.17KB	Share
SPL Starpharma completes US New Drug Application for VivaGel BV
30/04/18	PRICE SENSITIVE	147.44KB	Share
SPL Starpharma to present at OTCQX Virtual Investor Conference
11/04/18		53.5KB	Share
SPL Change in Director's Interest Notice - J Fairley
21/03/18		131.78KB	Share
SPL Change in Director's Interest Notice - R Thomas
20/03/18		116.78KB	Share
SPL Appendix 3B
20/03/18		183.54KB	Share
SPL Change in Director's Interest Notice - R Thomas
15/03/18		116.9KB	Share
SPL Change in Director's Interest Notice - P Turvey
12/03/18		116.36KB	Share
SPL Change in Director's Interest Notice - J Fairley
12/03/18		74.12KB	Share
SPL Change in Director's Interest Notice - R Thomas
05/03/18		139.99KB	Share
SPL Interim Report and Half-Yearly Financial Results
26/02/18	PRICE SENSITIVE	467.21KB	Share
SPL Starpharma receives $3.7M R&D tax incentive refund
22/02/18	PRICE SENSITIVE	125.51KB	Share
SPL Shareholder Update February 2018
19/02/18		1.51MB	Share
SPL Starpharma to commence DEP cabazitaxel phase 1/2 trial
31/01/18	PRICE SENSITIVE	146.38KB	Share
SPL Appendix 3B
29/01/18		186.06KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
25/01/18	PRICE SENSITIVE	690.96KB	Share
SPL VivaGel BV treatment clinical submission under rolling NDA
21/12/17	PRICE SENSITIVE	166.62KB	Share
SPL Change in Director's Interest Notice - J Fairley
11/12/17		257.79KB	Share
SPL Appendix 3B
11/12/17		189.62KB	Share
SPL Change in Director's Interest Notice - R Thomas
05/12/17		257.4KB	Share
SPL Amended Constitution
29/11/17		898.26KB	Share
SPL AGM Results
29/11/17		131.25KB	Share
SPL AGM - Chairman address and CEO presentation
29/11/17		5.95MB	Share
SPL NDA submission for VivaGel BV in the US
21/11/17	PRICE SENSITIVE	159.47KB	Share
SPL Change in Director's Interest Notice - J Fairley
08/11/17		70.24KB	Share
SPL Change in Director's Interest Notice - R Thomas
31/10/17		118.79KB	Share
SPL Notice of Annual General Meeting/Proxy Form
27/10/17		642.28KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
26/10/17	PRICE SENSITIVE	231.4KB	Share
SPL VivaGel BV granted marketing approval in Australia
25/10/17	PRICE SENSITIVE	83.81KB	Share
SPL Shareholder Update October 2017
18/10/17		1.23MB	Share
SPL Appendix 3B
12/10/17		115.54KB	Share
SPL Starpharma and Peter Mac Cancer Centre awarded DEP Grant
09/10/17	PRICE SENSITIVE	58.58KB	Share
SPL Change in Director's Interest Notice - J Fairley
05/10/17		128.52KB	Share
SPL Appendix 3B
05/10/17		185.46KB	Share
SPL Notification of AGM date
02/10/17		115.87KB	Share
SPL AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
28/09/17	PRICE SENSITIVE	138.54KB	Share
SPL DEP docetaxel positive phase 1 results, phase 2 commences
22/09/17	PRICE SENSITIVE	363.52KB	Share
SPL Appendix 4G - Corporate Governance Statement
28/08/17		186.46KB	Share
SPL Annual report and full year financial results
28/08/17	PRICE SENSITIVE	1.77MB	Share
SPL Starpharma to present at Finance News Network Investor Event
24/08/17		122.2KB	Share
SPL Appendix 3B
21/08/17		184.22KB	Share
SPL Starpharma and Monash awarded STEM Business Fellowships
09/08/17	PRICE SENSITIVE	138.26KB	Share
SPL Successful VivaGel Phase 3 results and NDA planned for rBV
07/08/17	PRICE SENSITIVE	424.4KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
19/07/17	PRICE SENSITIVE	169.14KB	Share
SPL Shareholder Update July 2017
04/07/17		710.25KB	Share
SPL VivaGel BV phase 3 results timing and commercialisation
04/07/17	PRICE SENSITIVE	173.13KB	Share
SPL Appendix 3B
14/06/17		184.95KB	Share
SPL Sale of Agrochemicals Business Investor Presentation
14/06/17		986.91KB	Share
SPL Starpharma sells Agrochemicals business to Agrium for $35M
14/06/17	PRICE SENSITIVE	179.92KB	Share
SPL DEP irinotecan outperforms irinotecan in cancer models
06/06/17	PRICE SENSITIVE	349.39KB	Share

REFRESH

First 3 4 5 6 7

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories